These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20177016)

  • 1. [18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.
    De Giorgi U; Amadori D
    J Clin Oncol; 2010 May; 28(15):e236-7; author reply e238. PubMed ID: 20177016
    [No Abstract]   [Full Text] [Related]  

  • 2. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
    Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
    J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
    Wei LH; Su H; Hildebrandt IJ; Phelps ME; Czernin J; Weber WA
    Clin Cancer Res; 2008 Jun; 14(11):3416-26. PubMed ID: 18519772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common corruption of the mTOR signaling network in human tumors.
    Menon S; Manning BD
    Oncogene; 2008 Dec; 27 Suppl 2(0 2):S43-51. PubMed ID: 19956179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of PET for monitoring cancer therapy and for predicting outcome.
    Weber WA
    J Nucl Med; 2005 Jun; 46(6):983-95. PubMed ID: 15937310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
    Subbiah IM; Brown RE; Fallon MB
    Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
    [No Abstract]   [Full Text] [Related]  

  • 7. Are we ready to move away from nature?: the rapamycin story.
    Mita M; Mita A
    Target Oncol; 2011 Jun; 6(2):63-4. PubMed ID: 21674158
    [No Abstract]   [Full Text] [Related]  

  • 8. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
    Wang M; Gao M; Miller KD; Sledge GW; Zheng QH
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1569-74. PubMed ID: 22297110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin: the cure for all that ails.
    Hasty P
    J Mol Cell Biol; 2010 Feb; 2(1):17-9. PubMed ID: 19805415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Instant gratification must wait.
    Divgi C
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):979-80. PubMed ID: 16810529
    [No Abstract]   [Full Text] [Related]  

  • 13. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
    van Veelen W; Korsse SE; van de Laar L; Peppelenbosch MP
    Oncogene; 2011 May; 30(20):2289-303. PubMed ID: 21258412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.
    Hung KE; Maricevich MA; Richard LG; Chen WY; Richardson MP; Kunin A; Bronson RT; Mahmood U; Kucherlapati R
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1565-70. PubMed ID: 20080688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mTOR signaling for lung cancer therapy.
    Sun SY; Fu H; Khuri FR
    J Thorac Oncol; 2006 Feb; 1(2):109-11. PubMed ID: 17409838
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond FDG: Many Molecular Imaging Agents Are in Development.
    Brower V
    J Natl Cancer Inst; 2011 Jan; 103(1):13-5. PubMed ID: 21169540
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
    Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B
    Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.